Merck's SpringWorks Takeover Delivers a Drug Approval

Merck's SpringWorks takeover delivers a drug approval

Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.

Ezmekly becomes first approved EU therapy for NF1-PN in children and adults

EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

EU approves SpringWorks’ Ezmekly for neurofibromatosis type 1 treatment

This addresses symptomatic, inoperable plexiform neurofibromas (PN) in paediatric and adult patients with neurofibromatosis type 1 (NF1), starting from two years of age. Ezmekly is now the only The post EU approves SpringWorks’ Ezmekly for neurofibromatosis type 1 treatment appeared first on Pharmaceutical Business review.